Medical technology company Medtronic (MDT), whose colleagues include Boston Scientific (BSX) and Johnson & Johnson (JNJ), has not had a good year. The chart communicates a very bearish situation. But when a stock takes a significant dip, many investors wonder if it is time to buy.

Earlier in the week, the business reported disappointing fiscal first-quarter news. If that wasn't enough, UBS issued a downgrade on the shares. The firm has reduced the equity's status to neutral from buy, according to BloggingStocks' analyst calls article. The price target is $33. Medtronic finished Thursday's session at a quote of $32.28.

This past week, Warren Buffett's holding company, Berkshire Hathaway (BRK.A), gave an update on what its stock holdings look like, what stocks were added, which ones added to, and which ones it was selling. Though there aren't many major changes in the list, there are some telling points that most investors can study and learn how to invest like Mr. Buffett.

These are stocks he's added to or added in the last quarter:

• Becton Dickinson (BDX): Up 155,000 shares (total owned: 1.889 million shares).
• Fiserve Inc. (FISV): This is a new position of 4.4 million shares.
• Iron Mountain (IRM): Increased position by 206,000 shares. Has been buying this over the past several quarters with a starting position of 3.3722 million shares.

Here is a common sentiment about the stock market: "No fun at all. As I have said before, I believe it has turned into one big casino largely divorced from its original goal of providing capital to companies who produce something of value."

There's a lot of truth to what "granny" recently said to me in an e-mail. Fortunately she also noted "FYI Granny's up 5.86% + dividends." That would give her a gain of about 10% in the past ten months since I posted Where should granny put $50,000, suggesting a very conservative portfolio for an uncertain time.

Not only has she earned a very nice return, surpassing her CD account by 9.5% (20 fold), but she was able to do so with a great deal less volatility than the overall market most of us have lived through.

"Investing in conservative stocks to build or rebuild the core of your portfolio makes sense right now; investors should buy companies that have a long history of steady earnings and dividend growth, through good times and tough times," says J. Royden Ward.

The editor of the specialty newsletter, Cabot Benjamin Graham Value Letter, explains, "The obvious benefit of adhering to a disciplined system of value investing like ours is that you build long-term profits and, ideally, financial independence.

BP (BP) closed up $1.79 Monday to $38.65. The company reported a $17 billion loss Tuesday morning and announced it has replaced CEO Tony Hayward with Bob Dudley. Overall option implied volatility of 51 is below a level of 78 from June 28, according to Track Data, suggesting decreasing price movement.

Genzyme (GENZ) closed up $4.86 to $67.38. Sanofi-Aventis (SNY), GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) may be interested in making a play for GENZ, reports the Wall Street Journal. Overall option implied volatility of 40 is above GENZ 26-week average of 31, according to Track Data, suggesting larger price movement.

Update is by Stock Specialist Paul Foster of theflyonthewall.com.

Yesterday I was shocked by the response to a poll I conducted in this very same column where I suggested that six out-of-favor stocks were a buy and would out perform the over all market. The results left me puzzled for several reasons.

For one thing I have been blogging for Aol. for over four years and I cannot remember an occasion that there was so much unanimity on anything before. I expected approximately equal votes for each of four possible responses to my question, and an appreciable number that might think I was off my rocker. Instead, I was jolted to a new reality when 84% of the respondents agreed that the six toxic stocks would outperform.

The six stocks are Bank of America (BAC), Citigroup (C), General Electric (GE), BP p.l.c. (BP), Goldman Sachs (GS) and Transocean (RIG). I thought I was taking a contrarian position and based on recent market activity that would seem to be the case. This raises another question. If my readers are any reflection of the market, how could the market move in the opposite direction of such overwhelming sentiment?

Johnson & Johnson (JNJ) reported second-quarter net earnings and diluted earnings per share of $3.4 billion and $1.23, respectively. Taking an after-tax gain of $67 million out of the equation (stemming from the net impact of "litigation matters"), the company earned $1.21 per share and $3.4 billion. The consensus estimate called for earnings of $1.21 per share and revenue of $15.69 billion.

Quarterly revenue checked in at $15.33 billion. In addition, JNJ revised its full-year estimate, now expecting adjusted earnings between $4.65 and $4.75 per share. This new range includes the impact of the recalls of some OTC medicines, the suspension of production at a plant in Pennsylvania, and poor foreign-exchange rates.

"Our primary purpose is to assist investors in growing their capital and income base from which to derive cash for their current and future needs," says blue chip stock specialist Kelley Wright.

The editor of Investment Quality Trends explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation.

"The Timely Ten list of stocks is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years.

If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).

Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan.

Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81.

The Food and Drug Administration (FDA) recently gave Shire Plc (SHPGY) shareholders something to smile about when it approved Daytrana for treating patients between 13 and 17 years who suffer from Attention Deficit Hyperactivity Disorder (ADHD).

Daytrana is the only ADHD treatment that is available in a transdermal patch, which delivers methylphenidate through the skin into the bloodstream. It is already approved for use by patients between 6 and 12 years.

With this announcement, Shire -- which licensed Daytrana from Noven Pharmaceuticals -- stands to gain market share and increase revenues.

Let's go around one more time with American Eagle Outfitters (AEO), the retailer with the pristine balance sheet that designs and manufactures its own clothing line targeted at the 15 to 25 year old age group.

It was one of my successful picks for 2009, rising from $9.13 to a closing price of $16.98, with a 52 week high of $19.86. Today it is trading near its 52 week low of $11.35, opening at $11.61 and trading up at mid-day.

I think this eagle will soar again and surpass it's previous high.

"Since 2001, I've avoided big-name stocks because I thought they were too expensive. But now, for the first time in my career, I'm finding value in some big U.S. stocks... particularly in one sector: pharmaceuticals," says Dr. Steve Sjuggerud.

The editor of Daily Wealth explains, "Big drug companies are record cheap, investors have given up on them, and we might be seeing a glimmer of an uptrend. Below, we consider the case of Johnson & Johnson (JNJ).

"The share price is in the $50s today, like it was at its highs in 1999. But since then, the business has grown dramatically. Now, you get a whole lot more business for your investment buck.

Stories are starting to appear that "my pal Warren" is gearing up for a major foreign acquisition. One of my dear friends Randy S. is taking a post graduate business class at UCLA where this issue is a part of the course. He is supposed to figure out what non US companies Berkshire Hathaway (BRK.A/BRK.B), led by Warren Buffett, might be considering for investment.

Ahh yes, the prediction business, quite tricky indeed. Starting with some basics, in most cases I would stick to the time tested philosophy that past performance is not an indicator of future success. That said, I think in the case of Buffett, it does. There are many clues along the trail based on his past performance.

Here are some basic consistencies from the existing portfolio that I would expect to hold true going forward.

It looks like some members in Congress are not too happy about the way Johnson & Johnson (JNJ) has behaved in the aftermath of the recent recalls involving some medicinal products.

That may be, but I'll tell you, the stock is trading with a pretty cool dividend yield attached right now. At the time of this writing, shares were exchanging hands during the afternoon session at a price of $58.12. That means that the yield is about 3.7%.

"Fear is back and it can be seen in the internals. So what is one to do? What we always do: identify quality, establish value, and take advantage of opportunity when it presents itself," suggests Kelley Wright.

The editor of Investment Quality Trends -- an advisory service that assesses blue chip stocks by analyzing their historic dividend yield levels -- adds, "While all ships go out with the tide, value is eventually rewarded. Remember, we are in this for the long haul.

"Our current Timely Ten -- featured below -- is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years. Do we believe that all 10 will go up simultaneously or immediately? Of course not.